Flubromazolam
From Wikipedia, the free encyclopedia
Triazolobenzodiazepine drug
Pharmaceutical compound
Legal status
- BR: Class B1 (Psychoactive drugs)[1]
- CA: Schedule IV
- DE: Anlage II (Authorized trade only, not prescriptible)
- UK: Under Psychoactive Substances Act
- US: Schedule I
- Illegal in Sweden and Switzerland
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.428.311  |
| Chemical and physical data | |
| Formula | C17H12BrFN4 |
| Molar mass | 371.213 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) | |
Flubromazolam (JYI-73) [2][3][4] is a triazolobenzodiazepine (TBZD), which are benzodiazepine (BZD) derivatives.[5][6][7][8][9][10][11] Flubromazolam is reputed to be highly potent, and concerns have been raised that clonazolam and flubromazolam in particular may pose comparatively higher risks than other designer benzodiazepines, due to their ability to produce strong sedation and amnesia at oral doses of as little as 0.5 mg.[12][13][14] Life-threatening adverse reactions have been observed at doses of only 3 mg of flubromazolam.[15]
Sweden
Flubromazolam has been classified as an illegal substance in Sweden after seizures by customs and police, as well as indications from the EMCDDA of wider use as a recreational drug.[16]
Switzerland
Flubromazolam is illegal in Switzerland as of December 2015.[17]
United Kingdom
In the UK, flubromazolam has been classified as a Class C drug by the May 2017 amendment to The Misuse of Drugs Act 1971 along with several other designer benzodiazepine drugs.[18]
Australia
In Australia, flubromazolam is Schedule 9 under federal law.[19]
United States
Flubromazolam is controlled in Virginia and Wisconsin.[20] On 23 December 2022, the DEA announced it had begun consideration on the matter of placing Flubromazolam under temporary Schedule I status.[21] Later on 25 July 2023, the DEA published a pre-print notice that Flubromazolam would become temporarily scheduled as a Schedule I controlled substance from 26 July 2023 to 26 July 2025.[22] On July 25, 2025, and effective the following day, the DEA extended the temporary scheduling until July 26, 2026.[23]
See also
References
- ↑ Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
- ↑ Cook JM, et al. Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects. US7618958
- ↑ Borer R, Gerecke M, Kyburz E (22 October 1986). "Patent EP 0072029 B1 - Triazolobenzazepines, process and intermediates for their preparation and medicines containing them". Retrieved 6 August 2015.
- ↑ Hester JB, Rudzik AD, Kamdar BV (November 1971). "6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines which have central nervous system depressant activity". Journal of Medicinal Chemistry. 14 (11): 1078–81. doi:10.1021/jm00293a015. PMID 5165540.
- ↑ "Flubromazolam". Cayman Chemical. Retrieved 20 November 2015.
- ↑ Huppertz LM, Bisel P, Westphal F, Franz F, Auwärter V, Moosmann B (July 2015). "Characterization of the four designer benzodiazepines clonazolam, deschloroetizolam, flubromazolam, and meclonazepam, and identification of their in vitro metabolites". Forensic Toxicology. 33 (2): 388–395. doi:10.1007/s11419-015-0277-6. S2CID 33278305.
- ↑ Chaslot M, El Balkhi S, Robin T, Morichon J, Picard N, Saint-Marcoux F (June 2016). "Exploration des métabolites de 8 benzodiazépines de synthèse". Toxicologie Analytique et Clinique. 28 (2): S32. Bibcode:2016ToxAC..28S..32C. doi:10.1016/j.toxac.2016.03.053.
- ↑ Pettersson Bergstrand M, Helander A, Hansson T, Beck O (April 2017). "Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays". Drug Testing and Analysis. 9 (4): 640–645. doi:10.1002/dta.2003. PMID 27366870.
- ↑ Høiseth G, Tuv SS, Karinen R (November 2016). "Blood concentrations of new designer benzodiazepines in forensic cases". Forensic Science International. 268: 35–38. doi:10.1016/j.forsciint.2016.09.006. PMID 27685473.
- ↑ Manchester KR, Maskell PD, Waters L (March 2018). "Experimental versus theoretical log D7.4, pKa and plasma protein binding values for benzodiazepines appearing as new psychoactive substances" (PDF). Drug Testing and Analysis. 10 (8): 1258–1269. doi:10.1002/dta.2387. PMID 29582576. S2CID 31098917.
- ↑ Wohlfarth A, Vikingsson S, Roman M, Andersson M, Kugelberg FC, Green H, Kronstrand R (May 2017). "Looking at flubromazolam metabolism from four different angles: Metabolite profiling in human liver microsomes, human hepatocytes, mice and authentic human urine samples with liquid chromatography high-resolution mass spectrometry". Forensic Science International. Special Issue on the 54th Annual Meeting of the International Association of Forensic Toxicologists (TIAFT) Brisbane from 28 August to 1 September 2016. 274: 55–63. doi:10.1016/j.forsciint.2016.10.021. PMID 27863836.
- ↑ Moosmann B, King LA, Auwärter V (June 2015). "Designer benzodiazepines: A new challenge". World Psychiatry. 14 (2): 248. doi:10.1002/wps.20236. PMC 4471986. PMID 26043347.
- ↑ Huppertz LM, Moosmann B, Auwärter V (January 2018). "Flubromazolam - Basic pharmacokinetic evaluation of a highly potent designer benzodiazepine". Drug Testing and Analysis. 10 (1): 206–211. doi:10.1002/dta.2203. PMID 28378533.
- ↑ Edinoff AN, Nix CA, Odisho AS, Babin CP, Derouen AG, Lutfallah SC, Cornett EM, Murnane KS, Kaye AM, Kaye AD (2022). "Novel Designer Benzodiazepines: Comprehensive Review of Evolving Clinical and Adverse Effects". Neurology International. 14 (3): 648–663. doi:10.3390/neurolint14030053. PMC 9397074. PMID 35997362.
- ↑ Łukasik-Głębocka M, Sommerfeld K, Teżyk A, Zielińska-Psuja B, Panieński P, Żaba C (2016). "Flubromazolam--A new life-threatening designer benzodiazepine". Clinical Toxicology. 54 (1): 66–8. doi:10.3109/15563650.2015.1112907. PMID 26585557. S2CID 4114360.
- ↑ "Fler ämnen föreslås bli klassade som narkotika eller hälsofarlig vara" (in Swedish). Folkhälsomyndigheten. 28 March 2024.
- ↑ "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Der Bundesrat.
- ↑ "The Misuse of Drugs Act 1971 (Amendment) order 2017". Retrieved 4 April 2023.
- ↑ Scheduling proposals referred to the November 2015 meeting of the Advisory Committee on Medicines Scheduling (ACMS#16) 2.6 Flubromazolam
- ↑ "Wisconsin Legislature, Chapter 961". Wisconsin State Legislature. Retrieved 1 November 2025.
- ↑ "Schedules of Controlled Substances: Temporary Placement of Etizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Schedule I". Federal Register. 23 December 2022. Retrieved 4 April 2023.
- ↑ "Schedules of Controlled Substances: Temporary Placement of Etizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Schedule I" (PDF). Federal Register. DEA. 25 July 2023. Retrieved 25 July 2023.
- ↑ "Schedules of Controlled Substances: Extension of Temporary Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act". Federal Register. 25 July 2025. Retrieved 13 August 2025.